Which has better valuation & earnings, GLSI or CLYM?

Climb Bio is trading at a lower price-to-earnings ratio than Greenwich LifeSciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Greenwich LifeSciences N/A N/A -$19.36M -$1.54 N/A Climb Bio N/A N/A -$59.85M -$0.83 N/A

Is GLSI or CLYM more profitable?

Climb Bio's return on equity of -31.79% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Greenwich LifeSciences N/A -793.81% -295.32% Climb Bio N/A -31.79% -30.79%

Greenwich LifeSciences (GLSI) Competitors

$15.45 +0.39 (+2.59%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$15.59 +0.14 (+0.91%)

As of 09/11/2026 07:49 PM Eastern

Compare

GLSI vs. CLYM, ACRS, DBVT, SLN, and FDMT

Should you buy Greenwich LifeSciences stock or one of its competitors? Greenwich LifeSciences's main competitors and comparable companies include Climb Bio (CLYM), Aclaris Therapeutics (ACRS), DBV Technologies (DBVT), Silence Therapeutics (SLN), and 4D Molecular Therapeutics (FDMT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Greenwich LifeSciences compare to Climb Bio?

Greenwich LifeSciences (NASDAQ:GLSI) and Climb Bio (NASDAQ:CLYM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 51.5% of Greenwich LifeSciences shares are owned by company insiders. Comparatively, 2.6% of Climb Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Climb Bio had 10 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 11 mentions for Climb Bio and 1 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 1.76 beat Climb Bio's score of 0.66 indicating that Greenwich LifeSciences is being referred to more favorably in the media.

Company	Overall Sentiment
Greenwich LifeSciences	Very Positive
Climb Bio	Positive

Greenwich LifeSciences has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market. Comparatively, Climb Bio has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market.

Climb Bio's return on equity of -31.79% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-793.81%	-295.32%
Climb Bio	N/A	-31.79%	-30.79%

Greenwich LifeSciences presently has a consensus target price of $69.00, indicating a potential upside of 346.60%. Climb Bio has a consensus target price of $26.92, indicating a potential upside of 88.93%. Given Greenwich LifeSciences' higher probable upside, equities analysts clearly believe Greenwich LifeSciences is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00

Climb Bio is trading at a lower price-to-earnings ratio than Greenwich LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.54	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

Summary

Climb Bio beats Greenwich LifeSciences on 8 of the 14 factors compared between the two stocks.

How does Greenwich LifeSciences compare to Aclaris Therapeutics?

Greenwich LifeSciences (NASDAQ:GLSI) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

Greenwich LifeSciences has higher earnings, but lower revenue than Aclaris Therapeutics. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.54	N/A
Aclaris Therapeutics	$7.83M	95.00	-$64.92M	-$0.58	N/A

In the previous week, Aclaris Therapeutics had 5 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 6 mentions for Aclaris Therapeutics and 1 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 1.76 beat Aclaris Therapeutics' score of 0.69 indicating that Greenwich LifeSciences is being referred to more favorably in the media.

Company	Overall Sentiment
Greenwich LifeSciences	Very Positive
Aclaris Therapeutics	Positive

4.2% of Greenwich LifeSciences shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 51.5% of Greenwich LifeSciences shares are held by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Greenwich LifeSciences has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

Greenwich LifeSciences has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -921.50%. Aclaris Therapeutics' return on equity of -61.65% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-793.81%	-295.32%
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%

Greenwich LifeSciences presently has a consensus price target of $69.00, suggesting a potential upside of 346.60%. Aclaris Therapeutics has a consensus price target of $11.33, suggesting a potential upside of 113.03%. Given Greenwich LifeSciences' higher possible upside, equities research analysts clearly believe Greenwich LifeSciences is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11

Summary

Aclaris Therapeutics beats Greenwich LifeSciences on 10 of the 16 factors compared between the two stocks.

How does Greenwich LifeSciences compare to DBV Technologies?

Greenwich LifeSciences (NASDAQ:GLSI) and DBV Technologies (NASDAQ:DBVT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

Greenwich LifeSciences presently has a consensus price target of $69.00, indicating a potential upside of 346.60%. DBV Technologies has a consensus price target of $48.50, indicating a potential upside of 309.28%. Given Greenwich LifeSciences' higher possible upside, equities analysts plainly believe Greenwich LifeSciences is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Greenwich LifeSciences has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.95, suggesting that its share price is 195% less volatile than the broader market.

Greenwich LifeSciences has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. DBV Technologies' return on equity of -119.33% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-793.81%	-295.32%
DBV Technologies	-3,506.53%	-119.33%	-84.43%

4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 51.5% of Greenwich LifeSciences shares are owned by company insiders. Comparatively, 1.1% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Greenwich LifeSciences has higher earnings, but lower revenue than DBV Technologies. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.54	N/A
DBV Technologies	$5.64M	132.11	-$146.95M	-$3.51	N/A

In the previous week, DBV Technologies had 2 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 3 mentions for DBV Technologies and 1 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 1.76 beat DBV Technologies' score of 1.07 indicating that Greenwich LifeSciences is being referred to more favorably in the media.

Company	Overall Sentiment
Greenwich LifeSciences	Very Positive
DBV Technologies	Positive

Summary

DBV Technologies beats Greenwich LifeSciences on 8 of the 15 factors compared between the two stocks.

How does Greenwich LifeSciences compare to Silence Therapeutics?

Greenwich LifeSciences (NASDAQ:GLSI) and Silence Therapeutics (NASDAQ:SLN) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

Greenwich LifeSciences has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

Greenwich LifeSciences has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Silence Therapeutics' return on equity of -106.94% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-793.81%	-295.32%
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%

Greenwich LifeSciences has higher earnings, but lower revenue than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Greenwich LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.54	N/A
Silence Therapeutics	$560K	1,399.88	-$88.61M	-$1.28	N/A

4.2% of Greenwich LifeSciences shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 51.5% of Greenwich LifeSciences shares are held by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Greenwich LifeSciences currently has a consensus target price of $69.00, indicating a potential upside of 346.60%. Silence Therapeutics has a consensus target price of $53.50, indicating a potential upside of 310.91%. Given Greenwich LifeSciences' higher probable upside, equities research analysts clearly believe Greenwich LifeSciences is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Greenwich LifeSciences and Greenwich LifeSciences both had 1 articles in the media. Greenwich LifeSciences' average media sentiment score of 1.76 beat Silence Therapeutics' score of 1.18 indicating that Greenwich LifeSciences is being referred to more favorably in the media.

Company	Overall Sentiment
Greenwich LifeSciences	Very Positive
Silence Therapeutics	Positive

Summary

Silence Therapeutics beats Greenwich LifeSciences on 8 of the 15 factors compared between the two stocks.

How does Greenwich LifeSciences compare to 4D Molecular Therapeutics?

Greenwich LifeSciences (NASDAQ:GLSI) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Greenwich LifeSciences has higher earnings, but lower revenue than 4D Molecular Therapeutics. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.54	N/A
4D Molecular Therapeutics	$85.21M	8.54	-$140.11M	-$2.63	N/A

Greenwich LifeSciences has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.74, suggesting that its share price is 174% more volatile than the broader market.

4.2% of Greenwich LifeSciences shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 51.5% of Greenwich LifeSciences shares are held by insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, 4D Molecular Therapeutics had 3 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 4 mentions for 4D Molecular Therapeutics and 1 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 1.76 beat 4D Molecular Therapeutics' score of 1.35 indicating that Greenwich LifeSciences is being referred to more favorably in the media.

Company	Overall Sentiment
Greenwich LifeSciences	Very Positive
4D Molecular Therapeutics	Positive

Greenwich LifeSciences has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -194.74%. 4D Molecular Therapeutics' return on equity of -41.33% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-793.81%	-295.32%
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%

Greenwich LifeSciences currently has a consensus price target of $69.00, indicating a potential upside of 346.60%. 4D Molecular Therapeutics has a consensus price target of $29.63, indicating a potential upside of 124.94%. Given Greenwich LifeSciences' higher possible upside, analysts plainly believe Greenwich LifeSciences is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

4D Molecular Therapeutics beats Greenwich LifeSciences on 10 of the 16 factors compared between the two stocks.

Get Greenwich LifeSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GLSI vs. The Competition

Export

Metric	Greenwich LifeSciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$226.78M	$3.86B	$7.17B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-10.03	8.38	214.57	20.80
Price / Sales	N/A	1,378.81	633.76	90.54
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	515.00	15.12	10.33	6.20
Net Income	-$19.36M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-3.13%	-4.34%	-3.32%	-2.35%
1 Month Performance	-8.69%	-0.02%	-0.41%	-2.77%
1 Year Performance	37.58%	40.64%	19.21%	7.63%

Greenwich LifeSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GLSI Greenwich LifeSciences	2.7225 of 5 stars	$15.45 +2.6%	$69.00 +346.6%	+35.3%	$226.78M	N/A	N/A	3	Positive News
CLYM Climb Bio	3.0818 of 5 stars	$14.60 +6.3%	$23.08 +58.1%	+493.8%	$838.34M	N/A	N/A	9	Analyst Forecast
ACRS Aclaris Therapeutics	2.3031 of 5 stars	$6.00 -0.9%	$11.50 +91.8%	+170.1%	$838.22M	$7.83M	N/A	100	News Coverage
DBVT DBV Technologies	3.4489 of 5 stars	$13.19 -4.6%	$48.50 +267.7%	+21.0%	$829.39M	$5.64M	N/A	80	News Coverage Positive News Analyst Forecast
SLN Silence Therapeutics	3.0342 of 5 stars	$13.77 +1.7%	$53.50 +288.7%	+166.8%	$828.73M	$560K	N/A	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GLSI) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Greenwich LifeSciences (GLSI) Competitors

GLSI vs. CLYM, ACRS, DBVT, SLN, and FDMT

How does Greenwich LifeSciences compare to Climb Bio?

Summary

How does Greenwich LifeSciences compare to Aclaris Therapeutics?

Summary

How does Greenwich LifeSciences compare to DBV Technologies?

Summary

How does Greenwich LifeSciences compare to Silence Therapeutics?

Summary

How does Greenwich LifeSciences compare to 4D Molecular Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLSI vs. The Competition

Greenwich LifeSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Greenwich LifeSciences (GLSI) Competitors

GLSI vs. CLYM, ACRS, DBVT, SLN, and FDMT

How does Greenwich LifeSciences compare to Climb Bio?

Do insiders and institutionals have more ownership in GLSI or CLYM?

Does the media prefer GLSI or CLYM?

Which has more volatility and risk, GLSI or CLYM?

Is GLSI or CLYM more profitable?

Do analysts prefer GLSI or CLYM?

Which has better valuation & earnings, GLSI or CLYM?

Summary

How does Greenwich LifeSciences compare to Aclaris Therapeutics?

Which has preferable valuation & earnings, GLSI or ACRS?

Does the media prefer GLSI or ACRS?

Do insiders & institutionals hold more shares of GLSI or ACRS?

Which has more volatility & risk, GLSI or ACRS?

Is GLSI or ACRS more profitable?

Do analysts rate GLSI or ACRS?

Summary

How does Greenwich LifeSciences compare to DBV Technologies?

Do analysts rate GLSI or DBVT?

Which has more risk & volatility, GLSI or DBVT?

Is GLSI or DBVT more profitable?

Do institutionals & insiders believe in GLSI or DBVT?

Which has preferable earnings & valuation, GLSI or DBVT?

Does the media refer more to GLSI or DBVT?

Summary

How does Greenwich LifeSciences compare to Silence Therapeutics?

Which has more volatility & risk, GLSI or SLN?

Is GLSI or SLN more profitable?

Which has stronger valuation & earnings, GLSI or SLN?

Do institutionals and insiders believe in GLSI or SLN?

Do analysts rate GLSI or SLN?

Does the media refer more to GLSI or SLN?

Summary

How does Greenwich LifeSciences compare to 4D Molecular Therapeutics?

Which has higher valuation & earnings, GLSI or FDMT?

Which has more risk & volatility, GLSI or FDMT?

Do insiders and institutionals believe in GLSI or FDMT?

Does the media prefer GLSI or FDMT?

Is GLSI or FDMT more profitable?

Do analysts prefer GLSI or FDMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLSI vs. The Competition

Greenwich LifeSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools